Electric pulses may boost a drug's power against painful vascular malformations

NCT ID NCT07720570

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

Slow-flow vascular malformations — abnormal clusters of veins, capillaries, or lymph vessels — can cause pain, swelling, and appearance concerns. This study follows 60 children and adults who receive bleomycin electrosclerotherapy (BEST), a procedure that injects the drug bleomycin into the malformation and then applies brief electrical pulses to increase its local effect. Researchers track symptom changes and quality of life over six months using patient questionnaires and MRI scans, aiming to see whether BEST offers meaningful relief.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
bleomycin electrosclerotherapy (BEST) — a procedure that injects bleomycin into the malformation and applies brief electrical pulses to boost its effect
What this could lead to
If it works, BEST could become a standard, less invasive option to ease pain, swelling, and appearance concerns from slow-flow vascular malformations.
What could go wrong
This is a small observational study with no control group, so improvements may not be due to the treatment. Side effects from bleomycin or the electrical pulses are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VASCULAR MALFORMATIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Copenhagen University Hospital - Rigshospitalet

    Copenhagen, Capital Region of Denmark, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.